Source comparison
BPC-157 + TB-500: Research Dosing Comparison
| Peptide | Molecular Weight | Standard Dose Range | Injection Frequency | Half-Life | Primary Mechanism | Reconstitution (5mg vial) | Bottom Line Assessment ||—|—|—|—|—|—|—|| BPC-157 | 1419 Da | 200–500 mcg per injection | Twice daily (every 12 hours) | 4–6 h
This comparison does not assign a generated winner or score.
- | Peptide | Molecular Weight | Standard Dose Range | Injection Frequency | Half-Life | Primary Mechanism | Reconstitution (5mg vial) | Bottom Line Assessment ||—|—|—|—|—|—|—|| BPC-157 | 1419 Da | 200–500 mcg per injection | Twice daily (every 12 hours) | 4–6 hours | VEGF receptor stabilisation, angiogenesis, anti-inflammatory cytokine modulation | 2 mL bacteriostatic water = 2.5 mg/mL solution | Short half-life demands twice-daily dosing to maintain therapeutic plasma levels. Once-daily protocols waste 60% of the compound's potential || TB-500 | 4963 Da | 2–5 mg per injection | Twice weekly (non-consecutive days) | Approximately 2.5 days | Actin sequestration, cellular migration, collagen deposition | 2 mL bacteriostatic water = 2.5 mg/mL solution | Extended half-life allows infrequent dosing while sustaining therapeutic effect. Front-loading at 5 mg accelerates early-phase repair, then taper to 2 mg maintenance || Combined Stack |. | BPC: 500 mcg/day, TB: 4–10 mg/week | BPC twice dail